{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T06:20:09Z","timestamp":1768285209934,"version":"3.49.0"},"reference-count":60,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrinolog\u00eda, Diabetes y Nutrici\u00f3n (English ed.)"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.endien.2024.12.005","type":"journal-article","created":{"date-parts":[[2025,1,8]],"date-time":"2025-01-08T17:39:41Z","timestamp":1736357981000},"page":"26-36","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Reducing hyperuricemic events with SGLT2 inhibitors: An updated systematic review with meta-regression"],"prefix":"10.1016","volume":"72","author":[{"given":"Hamlet","family":"Ghukasyan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Denilsa Dinis","family":"Pedro Navalha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ignacio","family":"P\u00e9rez Romero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Vit\u00f3ria","family":"Prato Wolwacz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Artur","family":"Ghahramanyan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristiane Wen","family":"Tsing Ngan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Helena","family":"Siqueira Tavares de Melo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caroline","family":"Serafim Dagostin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luis","family":"G\u00f3mez-Lech\u00f3n Quir\u00f3s","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.endien.2024.12.005_bib0305","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1038\/nrrheum.2015.91","article-title":"Global epidemiology of gout: prevalence, incidence and risk factors","volume":"11","author":"Kuo","year":"2015","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.endien.2024.12.005_bib0310","doi-asserted-by":"crossref","first-page":"574","DOI":"10.3899\/jrheum.170806","article-title":"The rising incidence of gout and the increasing burden of comorbidities: a population-based study over 20 years","volume":"45","author":"Elfishawi","year":"2018","journal-title":"J Rheumatol"},{"key":"10.1016\/j.endien.2024.12.005_bib0315","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1002\/art.22466","article-title":"Prevalence of the metabolic syndrome in patients with gout: the Third National Health and Nutrition Examination Survey","volume":"57","author":"Choi","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.endien.2024.12.005_bib0320","doi-asserted-by":"crossref","first-page":"e50046","DOI":"10.1371\/journal.pone.0050046","article-title":"Reduced glomerular function and prevalence of gout: NHANES 2009-10","volume":"7","author":"Krishnan","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.endien.2024.12.005_bib0325","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1177\/2047487313514895","article-title":"Increased cardiovascular mortality associated with gout: a systematic review and meta-analysis","volume":"22","author":"Clarson","year":"2015","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.endien.2024.12.005_bib0330","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1136\/annrheumdis-2016-210588","article-title":"The unclosing premature mortality gap in gout: a general population-based study","volume":"76","author":"Fisher","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.endien.2024.12.005_bib0335","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1161\/CIRCULATIONAHA.107.703389","article-title":"Independent impact of gout on mortality and risk for coronary heart disease","volume":"116","author":"Choi","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.endien.2024.12.005_bib0340","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1093\/ndt\/gfu352","article-title":"Prevalence and correlates of gout in a large cohort of patients with chronic kidney disease: the German Chronic Kidney Disease (GCKD) study","volume":"30","author":"Jing","year":"2015","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.endien.2024.12.005_bib0345","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1056\/NEJMoa1710895","article-title":"Cardiovascular safety of febuxostat or allopurinol in patients with gout","volume":"378","author":"White","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.endien.2024.12.005_bib0350","first-page":"104","article-title":"Frequency and predictors of inappropriate management of recurrent gout attacks in a longitudinal study","volume":"33","author":"Neogi","year":"2006","journal-title":"J Rheumatol"},{"key":"10.1016\/j.endien.2024.12.005_bib0355","doi-asserted-by":"crossref","first-page":"174291","DOI":"10.1016\/j.ejphar.2021.174291","article-title":"A brief review of urate transporter 1 (URAT1) inhibitors for the treatment of hyperuricemia and gout: current therapeutic options and potential applications","volume":"907","author":"Song","year":"2021","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.endien.2024.12.005_bib0360","doi-asserted-by":"crossref","first-page":"499","DOI":"10.7326\/0003-4819-143-7-200510040-00009","article-title":"Pathogenesis of gout","volume":"143","author":"Choi","year":"2005","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.endien.2024.12.005_bib0365","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1002\/bdd.1909","article-title":"SGLT2 inhibitor lowers serum uric acid through alteration of uric acid transport activity in renal tubule by increased glycosuria","volume":"35","author":"Chino","year":"2014","journal-title":"Biopharm Drug Dispos"},{"key":"10.1016\/j.endien.2024.12.005_bib0370","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.semnephrol.2011.08.007","article-title":"Xanthine oxidase and uric acid in cardiovascular disease: clinical impact and therapeutic options","volume":"31","author":"Doehner","year":"2011","journal-title":"Semin Nephrol"},{"key":"10.1016\/j.endien.2024.12.005_bib0375","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/j.jacc.2014.04.083","article-title":"Metabolic impairment in heart failure: the myocardial and systemic perspective","volume":"64","author":"Doehner","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.endien.2024.12.005_bib0380","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/j.cardfail.2020.08.015","article-title":"Uric acid is a biomarker of oxidative stress in the failing heart: lessons learned from trials with allopurinol and SGLT2 inhibitors","volume":"26","author":"Packer","year":"2020","journal-title":"J Card Fail"},{"key":"10.1016\/j.endien.2024.12.005_bib0385","doi-asserted-by":"crossref","first-page":"101163","DOI":"10.1016\/j.eclinm.2021.101163","article-title":"Net effects of sodium-glucose co-transporter-2 inhibition in different patient groups: a meta-analysis of large placebo-controlled randomized trials","volume":"41","author":"Staplin","year":"2021","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.endien.2024.12.005_bib0390","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/S0140-6736(20)31824-9","article-title":"SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials","volume":"396","author":"Zannad","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.endien.2024.12.005_bib0395","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in heart failure with a preserved ejection fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.endien.2024.12.005_bib0400","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","article-title":"Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction","volume":"387","author":"Solomon","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.endien.2024.12.005_bib0405","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/S0140-6736(22)01429-5","article-title":"SGLT-2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials","volume":"400","author":"Vaduganathan","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.endien.2024.12.005_bib0410","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1016\/S0140-6736(22)02074-8","article-title":"Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials","volume":"400","author":"Nuffield Department of Population Health Renal Studies Group","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.endien.2024.12.005_bib0415","doi-asserted-by":"crossref","DOI":"10.1155\/2022\/7520632","article-title":"Impacts of sodium\/glucose cotransporter-2 inhibitors on circulating uric acid concentrations: a systematic review and meta-analysis","volume":"2022","author":"Akbari","year":"2022","journal-title":"J Diabetes Res"},{"key":"10.1016\/j.endien.2024.12.005_bib0420","doi-asserted-by":"crossref","DOI":"10.1177\/20406223221083509","article-title":"Effect of sodium-glucose cotransporter-2 (SGLT2) inhibitors on serum urate levels in patients with and without diabetes: a systematic review and meta-regression of 43 randomized controlled trials","volume":"13","author":"Yip","year":"2022","journal-title":"Ther Adv Chronic Dis"},{"key":"10.1016\/j.endien.2024.12.005_bib0425","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1007\/s00592-022-01866-3","article-title":"Can SGLT2 inhibitors prevent incident gout? A systematic review and meta-analysis","volume":"59","author":"Banerjee","year":"2022","journal-title":"Acta Diabetol"},{"key":"10.1016\/j.endien.2024.12.005_bib0430","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2023.1158153","article-title":"Sodium-glucose cotransporter-2 inhibitors use and the risk of gout: a systematic review and meta-analysis","volume":"14","author":"Lai","year":"2023","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.endien.2024.12.005_bib0435","doi-asserted-by":"crossref","first-page":"2697","DOI":"10.1111\/dom.15157","article-title":"Serum uric acid lowering and effects of sodium-glucose cotransporter-2 inhibitors on gout: a meta-analysis and meta-regression of randomized controlled trials","volume":"25","author":"Banerjee","year":"2023","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.endien.2024.12.005_bib0440","series-title":"Cochrane handbook for systematic reviews of interventions version 6.3 (updated February 2022). Cochrane","year":"2022"},{"key":"10.1016\/j.endien.2024.12.005_bib0445","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.endien.2024.12.005_bib0450","unstructured":"Navalha D, Ghukasyan H, P\u00e9rez Romero I, Prato Wolwacz MV, Siqueira Tavares de Melo MH, Tsing Ngan CW, et al. Sodium-glucose cotransporter-2 inhibitor use can decrease the incidence of clinically relevant hyperuricemic events: a systematic review and meta-analysis. PROSPERO 2023 CRD42023442077. Available from: https:\/\/www.crd.york.ac.uk\/prospero\/display_record.php?ID=CRD42023442077."},{"key":"10.1016\/j.endien.2024.12.005_bib0455","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.endien.2024.12.005_bib0460","doi-asserted-by":"crossref","first-page":"i4919","DOI":"10.1136\/bmj.i4919","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"key":"10.1016\/j.endien.2024.12.005_bib0465","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2204233","article-title":"Empagliflozin in patients with chronic kidney disease","volume":"388","author":"The EMPA-KIDNEY Collaborative Group","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.endien.2024.12.005_bib0470","doi-asserted-by":"crossref","first-page":"2469","DOI":"10.1007\/s10067-023-06647-z","article-title":"Sodium glucose cotransporter 2 inhibitors and gout risk: a sequence symmetry analysis","volume":"42","author":"Wood","year":"2023","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.endien.2024.12.005_bib0475","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1111\/dom.14559","article-title":"Empagliflozin and uric acid metabolism in diabetes: a post hoc analysis of the EMPA-REG OUTCOME trial","volume":"24","author":"Ferreira","year":"2022","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.endien.2024.12.005_bib0480","doi-asserted-by":"crossref","first-page":"e220","DOI":"10.1016\/S2665-9913(19)30078-5","article-title":"The effects of canagliflozin on gout in type 2 diabetes: a post-hoc analysis of the CANVAS Program","volume":"1","author":"Li","year":"2019","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.endien.2024.12.005_bib0485","doi-asserted-by":"crossref","first-page":"3435","DOI":"10.1093\/eurheartj\/ehac320","article-title":"Uric acid and sodium-glucose cotransporter-2 inhibition with empagliflozin in heart failure with reduced ejection fraction: the EMPEROR-reduced trial","volume":"43","author":"Doehner","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.endien.2024.12.005_bib0490","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1001\/jamacardio.2022.5608","article-title":"Association of dapagliflozin use with clinical outcomes and the introduction of uric acid-lowering therapy and colchicine in patients with heart failure with and without gout: a patient-level pooled meta-analysis of DAPA-HF and DELIVER","volume":"8","author":"Butt","year":"2023","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.endien.2024.12.005_bib0495","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2023.155468","article-title":"Uric acid and treatment with empagliflozin in heart failure with preserved ejection fraction (HFpEF): the EMPEROR-Preserved Trial","volume":"142","author":"Green","year":"2023","journal-title":"Metabolism"},{"key":"10.1016\/j.endien.2024.12.005_bib0500","doi-asserted-by":"crossref","first-page":"186","DOI":"10.7326\/M19-2610","article-title":"Assessing the risk for gout with sodium-glucose cotransporter-2 inhibitors in patients with type 2 diabetes: a population-based cohort study","volume":"172","author":"Fralick","year":"2020","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.endien.2024.12.005_bib0505","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1002\/pds.5252","article-title":"Sodium-glucose cotransporter-2 inhibitors and the risk of gout: a Danish population based cohort study and symmetry analysis","volume":"30","author":"Lund","year":"2021","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.endien.2024.12.005_bib0510","doi-asserted-by":"crossref","first-page":"e2135353","DOI":"10.1001\/jamanetworkopen.2021.35353","article-title":"Association of sodium-glucose transport protein 2 inhibitor use for type 2 diabetes and incidence of gout in Taiwan","volume":"4","author":"Chung","year":"2021","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.endien.2024.12.005_bib0515","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.7326\/M23-0724","article-title":"Comparative effectiveness of sodium-glucose cotransporter-2 inhibitors for recurrent gout flares and gout-primary emergency department visits and hospitalizations: a general population cohort study","volume":"176","author":"McCormick","year":"2023","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.endien.2024.12.005_bib0520","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1111\/dom.14858","article-title":"Sodium-glucose cotransporter-2 inhibitors and the risk of gout in patients with type 2 diabetes mellitus: a propensity-score-matched, new-user design study with an active comparator using the IQVIA Medical Research Data UK database","volume":"25","author":"Subramanian","year":"2023","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.endien.2024.12.005_bib0525","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1093\/rheumatology\/keac509","article-title":"Lower risk of gout in sodium glucose cotransporter 2 (SGLT2) inhibitors versus dipeptidyl peptidase-4 (DPP4) inhibitors in type-2 diabetes","volume":"62","author":"Zhou","year":"2023","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.endien.2024.12.005_bib0530","doi-asserted-by":"crossref","first-page":"e2330885","DOI":"10.1001\/jamanetworkopen.2023.30885","article-title":"Gout flares and mortality after sodium-glucose cotransporter-2 inhibitor treatment for gout and type 2 diabetes","volume":"6","author":"Wei","year":"2023","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.endien.2024.12.005_bib0535","doi-asserted-by":"crossref","first-page":"927661","DOI":"10.3389\/fendo.2022.927661","article-title":"Clinical characteristics of inpatients with new-onset diabetes mellitus in eastern China: based on novel clustering analysis","volume":"13","author":"Song","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.endien.2024.12.005_bib0540","first-page":"25","article-title":"Hyperuricemia and insulin resistance","volume":"78","author":"Vuorinen-Markkola","year":"1994","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.endien.2024.12.005_bib0545","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1001\/archinte.168.10.1104","article-title":"Long-term cardiovascular mortality among middle-aged men with gout","volume":"168","author":"Krishnan","year":"2008","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.endien.2024.12.005_bib0550","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1186\/s13075-020-02299-5","article-title":"Epidemiology of gout in Hong Kong: a population-based study from 2006 to 2016","volume":"22","author":"Tsoi","year":"2020","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.endien.2024.12.005_bib0555","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1002\/acr.24180","article-title":"2020 American College of Rheumatology Guideline for the management of gout","volume":"72","author":"FitzGerald","year":"2020","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.endien.2024.12.005_bib0560","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1592\/phco.28.4.437","article-title":"Comparison of drug adherence rates among patients with seven different medical conditions","volume":"28","author":"Briesacher","year":"2008","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.endien.2024.12.005_bib0565","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1136\/annrheumdis-2015-208237","article-title":"2015 Gout classification criteria: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative","volume":"74","author":"Neogi","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.endien.2024.12.005_bib0570","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1186\/s12891-015-0614-2","article-title":"Validity of gout diagnosis in Swedish primary and secondary care \u2013 a validation study","volume":"16","author":"Dehlin","year":"2015","journal-title":"BMC Musculoskelet Disord"},{"key":"10.1016\/j.endien.2024.12.005_bib0575","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1002\/pds.4044","article-title":"Validation of claims-based algorithms for gout flares","volume":"25","author":"MacFarlane","year":"2016","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.endien.2024.12.005_bib0580","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1002\/acr.22324","article-title":"Using natural language processing and machine learning to identify gout flares from electronic clinical notes","volume":"66","author":"Zheng","year":"2014","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.endien.2024.12.005_bib0585","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2100028","article-title":"Comparative effectiveness of allopurinol and febuxostat in gout management","volume":"1","author":"O\u2019Dell","year":"2022","journal-title":"NEJM Evid"},{"key":"10.1016\/j.endien.2024.12.005_bib0590","doi-asserted-by":"crossref","first-page":"535","DOI":"10.7326\/M18-1167","article-title":"Relationship of interleukin-1\u03b2 blockade with incident gout and serum uric acid levels: exploratory analysis of a randomized controlled trial","volume":"169","author":"Solomon","year":"2018","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.endien.2024.12.005_bib0595","doi-asserted-by":"crossref","first-page":"5276","DOI":"10.1038\/s41598-018-23420-4","article-title":"Canagliflozin inhibits interleukin-1\u03b2-stimulated cytokine and chemokine secretion in vascular endothelial cells by AMP-activated protein kinase-dependent and -independent mechanisms","volume":"8","author":"Mancini","year":"2018","journal-title":"Sci Rep"},{"key":"10.1016\/j.endien.2024.12.005_bib0600","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1016\/S0140-6736(16)00346-9","article-title":"Gout","volume":"388","author":"Dalbeth","year":"2016","journal-title":"Lancet"}],"container-title":["Endocrinolog\u00eda, Diabetes y Nutrici\u00f3n (English ed.)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2530018024001410?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2530018024001410?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,10]],"date-time":"2025-01-10T10:04:43Z","timestamp":1736503483000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2530018024001410"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":60,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["S2530018024001410"],"URL":"https:\/\/doi.org\/10.1016\/j.endien.2024.12.005","relation":{},"ISSN":["2530-0180"],"issn-type":[{"value":"2530-0180","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Reducing hyperuricemic events with SGLT2 inhibitors: An updated systematic review with meta-regression","name":"articletitle","label":"Article Title"},{"value":"Endocrinolog\u00eda, Diabetes y Nutrici\u00f3n (English ed.)","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.endien.2024.12.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 SEEN and SED. Published by Elsevier Espa\u00f1a, S.L.U. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}